Healthcare Services

Vulvar Cancer Market Forecast Through 2030 with Industry Insights

April 28, 2026April 28, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Estimated Market Size Of The Vulvar Cancer Market In 2026, And How Will Its Value Evolve By 2030?

The vulvar cancer market has demonstrated robust growth in recent years. Its value is projected to rise from $0.62 billion in 2025 to $0.67 billion in 2026, progressing at a compound annual growth rate (CAGR) of 8.9%. Historically, this expansion has been influenced by increased awareness of gynecologic cancers, the availability of specialized surgical oncology expertise, the enlargement of hospital oncology departments, the implementation of radiation therapy techniques, and advancements in pathology diagnostics.

The vulvar cancer market is anticipated to experience substantial growth over the next few years. It is expected to reach $0.94 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.8%. This expansion during the forecast period can be attributed to escalating investments in precision oncology, the increasing embrace of biologic and immunotherapies, the broadened monitoring of HPV vaccination impact, an intensified focus on personalized treatment planning, and advancements in diagnostic imaging technologies. Key trends anticipated in this period include a greater adoption of targeted cancer therapies, a rising use of minimally invasive surgical procedures, an amplified focus on early diagnosis and screening, the proliferation of multimodal treatment approaches, and an enhanced integration of personalized oncology care.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21318&type=smp

What Major Factors Are Driving The Vulvar Cancer Market Forward?

The future expansion of the vulvar cancer market is anticipated to be fueled by greater financial commitments to oncology research and medicine. These investments represent financial resources directed by governments, pharmaceutical firms, research bodies, and private funders to improve the comprehension, avoidance, identification, and cure of cancer. The surge in oncology research and medicine funding stems from factors like the escalating worldwide cancer burden, progress in precision medicine, a rising need for novel treatments, the expansion of clinical trials, public and private funding programs, and the creation of targeted and immunotherapeutic interventions. Such investments bolster efforts against vulvar cancer through fostering breakthroughs in early detection, improving treatment modalities like targeted therapies and immunotherapy, financing clinical trials for superior medications, enhancing infrastructure for pediatric cancer care, and encouraging inventive research to grasp the disease’s biology and progression more thoroughly. For example, in May 2024, data from the IQVIA, an India-based information technology company specializing in advanced analytics, indicated that worldwide expenditure on cancer medication reached $223 billion in 2023, signifying a $25 billion growth from 2022, and is projected to hit $409 billion by 2028. Consequently, augmented investments in oncology research and medicine are propelling the vulvar cancer market.

Vulvar Cancer Market Driver: The Impact Of Personalized Medicine On Market Growth

How Is The Vulvar Cancer Market Broken Down By Segment Categories?

The vulvar cancer market covered in this report is segmented –

1) By Cancer Type: Vulvar Squamous Cell Carcinoma, Vulvar Melanoma, Adenocarcinoma, Basal Cell Carcinoma

2) By Treatment Type: Chemotherapy, Surgery, Laser Surgery, Excision, Skinning Vulvectomy, Radical Vulvectomy, Radiation Therapy, Biologic Therapy

3) By Distribution Channel: Online Channel, Offline Channel

4) By End Users: Hospitals And Clinics, Research And Academic Institutes, Other End Users

Subsegments:

1) By Vulvar Squamous Cell Carcinoma: Keratinizing Squamous Cell Carcinoma, Non-Keratinizing Squamous Cell Carcinoma, Verrucous Carcinoma

2) By Vulvar Melanoma: Mucosal Melanoma, Acral Lentiginous Melanoma, Nodular Melanoma

3) By Adenocarcinoma: Bartholin Gland Adenocarcinoma, Extramammary Paget’s Disease-Associated Adenocarcinoma, Sweat Gland Adenocarcinoma

4) By Basal Cell Carcinoma: Superficial Basal Cell Carcinoma, Nodular Basal Cell Carcinoma, Morpheaform (Sclerosing) Basal Cell Carcinoma

Which Trends Are Impacting The Progress Of The Vulvar Cancer Market?

Major companies engaged in the vulvar cancer market are intensifying their efforts on innovations in cancer therapy, notably alpha-radiation cancer therapy, to elevate treatment efficacy and patient outcomes. This alpha-radiation treatment involves delivering targeted alpha particles directly to tumor cells, which induces localized damage to cancerous tissue while preserving surrounding healthy tissue. An illustrative example occurred in May 2023 when Alpha Tau Medical Ltd., an Israel-based company, disclosed the inaugural application of its Alpha DaRT alpha-radiation cancer therapy for managing squamous cell carcinoma of the vulva. The ongoing study, conducted at Addenbrooke’s Hospital under the Cambridge University Hospitals NHS Foundation Trust, intends to recruit 10 participants to evaluate the safety and effectiveness of this therapy. Alpha DaRT presents a targeted, minimally invasive approach, underscoring its potential as a non-surgical treatment alternative for vulvar cancer.

Which Players Are Present In The Vulvar Cancer Market Space?

Major companies operating in the vulvar cancer market are F. Hoffmann-La Roche Ltd, Merck And Co., Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Amgen Inc., Regeneron Pharmaceuticals Inc., Intuitive Surgical Operations Inc., Elekta AB, Accuray Incorporated, Xencor, ISA Pharmaceuticals BV, Alpha Tau Medical Ltd, AstraZeneca PLC, Johnson & Johnson, Pfizer Inc, Eli Lilly and Company, AbbVie Inc, Astellas Pharma Inc, Takeda Pharmaceutical Company Ltd, Bayer AG, Ipsen, Gilead Sciences Inc

Get The Full Vulvar Cancer Market Report:

https://www.thebusinessresearchcompany.com/report/vulvar-cancer-global-market-report

Which Region Has The Greatest Market Share In The Vulvar Cancer Market?

North America was the largest region in the vulvar cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the vulvar cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Vulvar Cancer Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/vulvar-cancer-global-market-report

Browse Through More Reports Similar to the Global Vulvar Cancer Market 2026, By The Business Research Company

Gynecological Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/gynecological-cancer-drugs-global-market-report

Vaginal Sling Market Report

https://www.thebusinessresearchcompany.com/report/vaginal-sling-global-market-report

Genital Warts Market Report

https://www.thebusinessresearchcompany.com/report/genital-warts-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795